MCID: SJG008
MIFTS: 61

Sjogren Syndrome

Categories: Bone diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Sjogren Syndrome

MalaCards integrated aliases for Sjogren Syndrome:

Name: Sjogren Syndrome 57 12 20 36 17
Sjogren's Syndrome 12 43 42 44 15 71
Sicca Syndrome 57 12 20 43 71
Keratoconjunctivitis Sicca 43 71
Sjogren-Gougerot Syndrome 20 43
Sjögren's Syndrome 74 53
Keratoconjunctivitis Sicca-Xerostomia 43
Secreto-Inhibitor-Xerodermostenosis 43
Dacryosialoadenopathia Atrophicans 43
Primary Sjogren-Gougerot Syndrome 58
Gougerot-Houwer-Sjogren Syndrome 43
Gougerot-Sjogren Syndrome 43
Sjogrens Syndrome Primary 54
Primary Sjogren Syndrome 58
Dry Eye Syndromes 71
Sjogrens Syndrome 54
Xerodermosteosis 12
Sjögren Syndrome 43

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal recessive


HPO:

31
sjogren syndrome:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare systemic and rhumatological diseases


Summaries for Sjogren Syndrome

MedlinePlus Genetics : 43 Sjögren syndrome is a disorder whose main features are dry eyes and a dry mouth. The condition typically develops gradually beginning in middle adulthood, but it can occur at any age.Sjögren syndrome is classified as an autoimmune disorder, one of a large group of conditions that occur when the immune system attacks the body's own tissues and organs. In Sjögren syndrome, the immune system primarily attacks the glands that produce tears (the lacrimal glands) and saliva (the salivary glands), impairing the glands' ability to secrete these fluids.Dry eyes may lead to itching, burning, a feeling of sand in the eyes, blurry vision, or intolerance of bright or fluorescent lighting. A dry mouth can feel chalky or full of cotton, and affected individuals may have difficulty speaking, tasting food, or swallowing. Because saliva helps protect the teeth and the tissues of the oral cavity, people with Sjögren syndrome are at increased risk of tooth decay and infections in the mouth.In most people with Sjögren syndrome, dry eyes and dry mouth are the primary features of the disorder, and general health and life expectancy are largely unaffected. However, in some cases the immune system also attacks and damages other organs and tissues. This complication is known as extraglandular involvement. Affected individuals may develop inflammation in connective tissues, which provide strength and flexibility to structures throughout the body. Disorders involving connective tissue inflammation are sometimes called rheumatic conditions. In Sjögren syndrome, extraglandular involvement may result in painful inflammation of the joints and muscles; dry, itchy skin and skin rashes; chronic cough; a hoarse voice; kidney and liver problems; numbness or tingling in the hands and feet; and, in women, vaginal dryness. Prolonged and extreme tiredness (fatigue) severe enough to affect activities of daily living may also occur in this disorder. A small number of people with Sjögren syndrome develop lymphoma, a blood-related cancer that causes tumor formation in the lymph nodes.Some individuals who are first diagnosed with another rheumatic disorder, such as rheumatoid arthritis or systemic lupus erythematosus, later develop the dry eyes and dry mouth characteristic of Sjögren syndrome. Other autoimmune disorders can also develop after the onset of Sjögren syndrome. In all, about half of all individuals with Sjögren syndrome also have another autoimmune disorder.

MalaCards based summary : Sjogren Syndrome, also known as sjogren's syndrome, is related to raynaud disease and mikulicz disease, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Sjogren Syndrome is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Toll-like receptor signaling pathway and JAK-STAT signaling pathway. The drugs Fluorometholone and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and pancreas, and related phenotypes are keratoconjunctivitis sicca and xerostomia

Disease Ontology : 12 An autoimmune disease that involves attack of immune cells which destroy the exocrine glands that produce tears and saliva.

GARD : 20 Sjogren syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjogren syndrome is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. The hallmark symptoms of Sjogren syndrome are dry mouth and dry eyes. In addition, Sjogren syndrome may cause skin, nose, and vaginal dryness. It also may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain. Treatment focuses on the symptoms in each person and may include moisture replacement therapies, nonsteroidal anti-inflammatory drugs and, in severe cases, corticosteroids or immunosuppressive drugs.

OMIM® : 57 Sjogren syndrome is an autoimmune disease that mainly affects the exocrine glands. It is clinically characterized by keratoconjunctivitis sicca and xerostomia (Goransson et al., 2006). See 200400 for association of Sjogren syndrome with achalasia in sisters. (270150) (Updated 05-Mar-2021)

MedlinePlus : 42 Sjogren's syndrome is an autoimmune disease. This means that your immune system attacks parts of your own body by mistake. In Sjogren's syndrome, it attacks the glands that make tears and saliva. This causes a dry mouth and dry eyes. You may have dryness in other places that need moisture, such as your nose, throat, and skin. Sjogren's can also affect other parts of the body, including your joints, lungs, kidneys, blood vessels, digestive organs, and nerves. Most people with Sjogren's syndrome are women. It usually starts after age 40. It is sometimes linked to other diseases such as rheumatoid arthritis and lupus. To make a diagnosis, doctors may use a medical history, physical exam, certain eye and mouth tests, blood tests, and biopsies. Treatment focuses on relieving symptoms. It can differ for each person; it depends on what parts of the body are affected. It may include artificial tears for dye eyes and sucking on sugar-free candy or drinking water often for a dry mouth. Medicines may help with severe symptoms. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 53 Sjögren's syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjögren's syndrome is also associated with rheumatic disorders such as rheumatoid arthritis. The hallmark symptoms of the disorder are dry mouth and dry eyes. In addition, Sjogren's syndrome may cause skin, nose, and vaginal dryness, and may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain. Sjögren's syndrome affects 1-4 million people in the United States. Most people are more than 40 years old at the time of diagnosis. Women are 9 times more likely to have Sjögren's syndrome than men.

KEGG : 36 Sjogren Syndrome (SS) is a chronic inflammatory systemic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands leading to sicca symptoms of the eyes and mouth. Several systemic and extraglandular manifestations can develop, including fatigue, arthritis, and involvement of organs such as the skin, lungs, and kidneys. SS may occur as a primary disorder or in association with other systemic autoimmune diseases, traditionally defined as secondary SS, such as rheumatoid arthritis, and systemic lupus erythematosus. Salivary secretions from these patients exhibit elevated levels of antibodies and cytokines. This is accompanied by a reduction in oral phosphate levels and xerostomia due to reduced salivary flow, which can lead to infections, progressive caries, dysphagia and oral pain. Current tests for SS include sialometry, salivary scintigraphy, sialography, serological tests or minor salivary gland biopsies. Recently, salivary biomarkers of SS has been investigated. The etiology of SS is still unclear. Since there is a familial aggregation of primary SS, however, genetic factors have been suspected for a long time. Initially, HLA haplotypes were shown to be associated with primary SS. Recently, polymorphisms in the genes IRF5 and STAT4 have been convincingly identified and replicated in several studies as susceptibility factors.

Wikipedia : 74 Sjögren's syndrome (SjS, SS) is a long-term autoimmune disease that affects the body's... more...

Related Diseases for Sjogren Syndrome

Diseases in the Sjogren Syndrome family:

Sjogren's Syndrome, Juvenile, Secondary to Autoimmune Disease

Diseases related to Sjogren Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1284)
# Related Disease Score Top Affiliating Genes
1 raynaud disease 31.9 TRIM21 SSB
2 mikulicz disease 31.9 TNFSF13B CA2
3 aplasia of lacrimal and salivary glands 31.9 SPTAN1 HSPG2 CHRM3
4 salivary gland disease 31.8 TRIM21 TNFSF13B SSB LTF
5 systemic scleroderma 31.7 TRIM21 RO60 CD40LG
6 diffuse infiltrative lymphocytosis syndrome 30.8 TRIM21 SSB
7 neonatal lupus erythematosus 30.8 TRIM21 SPTAN1
8 xerophthalmia 30.7 TRIM21 TNFSF13B SSB SPTAN1 RO60
9 mononeuritis multiplex 30.6 TRIM21 SSB
10 atrioventricular block 30.6 TRIM21 SSB RO60
11 sialadenitis 30.5 TRIM21 TNFSF13B SSB SPTAN1
12 purpura 30.5 TNFSF13B CD79A APOH
13 polyclonal hypergammaglobulinemia 30.5 TRIM21 TNFSF13B SSB
14 mononeuropathy 30.4 TRIM21 SSB
15 dyskinesia of esophagus 30.4 TRIM21 SSB
16 limited scleroderma 30.4 TRIM21 SSB SPTAN1 RO60
17 lupus erythematosus 30.4 TRIM21 SSB RO60 CD40LG CALR APOH
18 keratoconjunctivitis sicca 30.3 TRIM21 TNFSF13B SSB SPTAN1 RO60 LTF
19 cryoglobulinemia 30.3 TNFSF13B CD79A CD40LG
20 parotitis 30.3 TRIM21 SSB LTF CD79A
21 mixed connective tissue disease 30.3 TNFSF13B CD40LG APOH
22 immunoglobulin alpha deficiency 30.3 TNFSF13B CD79A CD40LG
23 autoimmune disease 30.2 TRIM21 TNFSF13B RO60 FAS CD79A CD40LG
24 connective tissue disease 30.2 TNFSF13B SSB HSPG2 CD40LG CALR APOH
25 chronic graft versus host disease 30.2 TNFSF13B CD79A
26 cutaneous lupus erythematosus 30.2 TRIM21 TNFSF13B RO60
27 antiphospholipid syndrome 30.2 CD79A CD40LG APOH
28 parotid disease 30.2 TRIM21 SSB
29 root caries 30.1 LTF CD79A
30 cryofibrinogenemia 30.1 CD79A CD40LG
31 vasculitis 30.1 TNFSF13B LTF CD79A CD40LG APOH
32 autoimmune pancreatitis 30.1 TNFSF13B SPTAN1 CA2
33 syphilis 30.0 FAS CD79A CD40LG APOH
34 third-degree atrioventricular block 30.0 TRIM21 SSB
35 common variable immunodeficiency 30.0 TNFSF13B FAS CD79A CD40LG
36 behcet syndrome 29.9 TNFSF13B FAS CD40LG APOH
37 heart block, congenital 29.9 TRIM21 TNFSF13B SSB SPTAN1 RO60 CALR
38 relapsing-remitting multiple sclerosis 29.9 TNFSF13B FAS CD40LG
39 systemic lupus erythematosus 29.7 TRIM21 TNFSF13B SSB RO60 FAS CD79A
40 thrombocytopenia 29.7 TRIM21 TNFSF13B FAS CD79A CD40LG CALR
41 marinesco-sjogren syndrome 11.8
42 retrovirus-associated myelopathy 11.2
43 tenorio syndrome 11.1
44 sjogren's syndrome, juvenile, secondary to autoimmune disease 11.1
45 reynolds syndrome 11.0
46 distal renal tubular acidosis 11.0
47 autoimmune inner ear disease 11.0
48 acquired generalized lipodystrophy 11.0
49 autoimmune polyglandular syndrome type 3 11.0
50 hypocomplementemic urticarial vasculitis 11.0

Comorbidity relations with Sjogren Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypothyroidism Ichthyosis Vulgaris
Osteoporosis Postinflammatory Pulmonary Fibrosis
Rheumatoid Arthritis Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Sjogren Syndrome:



Diseases related to Sjogren Syndrome

Symptoms & Phenotypes for Sjogren Syndrome

Human phenotypes related to Sjogren Syndrome:

58 31 (show top 50) (show all 84)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 keratoconjunctivitis sicca 58 31 hallmark (90%) Very frequent (99-80%) HP:0001097
2 xerostomia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000217
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 anxiety 58 31 frequent (33%) Frequent (79-30%) HP:0000739
5 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
6 tubulointerstitial nephritis 58 31 frequent (33%) Frequent (79-30%) HP:0001970
7 parotitis 58 31 frequent (33%) Frequent (79-30%) HP:0011850
8 chronic pain 58 31 frequent (33%) Frequent (79-30%) HP:0012532
9 polyarticular arthropathy 58 31 frequent (33%) Frequent (79-30%) HP:0005195
10 usual interstitial pneumonia 58 31 frequent (33%) Frequent (79-30%) HP:0031950
11 depressivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000716
12 muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0001324
13 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
14 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
15 dry skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0000958
16 vitiligo 58 31 occasional (7.5%) Occasional (29-5%) HP:0001045
17 thyroiditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100646
18 biliary cirrhosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002613
19 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
20 skin ulcer 58 31 occasional (7.5%) Occasional (29-5%) HP:0200042
21 myalgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003326
22 lymphoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002665
23 purpura 58 31 occasional (7.5%) Occasional (29-5%) HP:0000979
24 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
25 vasculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002633
26 abnormal cerebellum morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001317
27 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
28 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
29 sensory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0003474
30 myositis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100614
31 optic neuritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100653
32 functional motor deficit 58 31 occasional (7.5%) Occasional (29-5%) HP:0004302
33 raynaud phenomenon 58 31 occasional (7.5%) Occasional (29-5%) HP:0030880
34 bronchitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012387
35 lymphoproliferative disorder 58 31 occasional (7.5%) Occasional (29-5%) HP:0005523
36 normocytic anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001897
37 cryoglobulinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100778
38 decreased serum complement c3 58 31 occasional (7.5%) Occasional (29-5%) HP:0005421
39 glomerulonephritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000099
40 erythema nodosum 58 31 occasional (7.5%) Occasional (29-5%) HP:0012219
41 arteritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012089
42 decreased serum complement c4 58 31 occasional (7.5%) Occasional (29-5%) HP:0045042
43 normochromic anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001895
44 nonproductive cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0031246
45 lichenoid skin lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0031452
46 abnormal pulmonary thoracic imaging finding 58 31 occasional (7.5%) Occasional (29-5%) HP:0031983
47 vaginal dryness 58 31 occasional (7.5%) Occasional (29-5%) HP:0031088
48 abnormality of the peripheral nervous system 58 31 occasional (7.5%) Occasional (29-5%) HP:0410008
49 seizure 31 occasional (7.5%) HP:0001250
50 increased circulating antibody level 31 occasional (7.5%) HP:0010702

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Head And Neck Mouth:
xerostomia

Immunology:
autoimmune disease

Head And Neck Eyes:
xerophthalmia, more severe in men

Skeletal:
rheumatoid arthritis

Genitourinary Kidneys:
interstitial nephritis

Clinical features from OMIM®:

270150 (Updated 05-Mar-2021)

UMLS symptoms related to Sjogren Syndrome:


back pain, sciatica, muscle cramp, eye manifestations, dryness of eye

GenomeRNAi Phenotypes related to Sjogren Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.4 CD79A CHRM3 LTF
2 Decreased viability GR00381-A-1 9.4 CD79A CHRM3 LTF
3 Decreased viability GR00381-A-3 9.4 CD79A CHRM3 LTF
4 Decreased viability GR00386-A-1 9.4 CD79A CHRM3
5 Decreased viability GR00402-S-2 9.4 LTF

MGI Mouse Phenotypes related to Sjogren Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.17 CA2 CD40LG CD79A CHRM3 FAS RO60

Drugs & Therapeutics for Sjogren Syndrome

Drugs for Sjogren Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 294)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Ethanol Approved Phase 4 64-17-5 702
4
Pilocarpine Approved, Investigational Phase 4 92-13-7, 54-71-7 5910
5
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
6
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
7
Allantoin Approved Phase 4 97-59-6 204
8 sodium fluoride Approved Phase 4 7681-49-4
9
Dimenhydrinate Approved Phase 4 523-87-5 441281
10
Sorbitol Approved Phase 4 50-70-4 5780
11
Glycerol Approved, Investigational Phase 4 56-81-5 753
12
Zinc Approved, Investigational Phase 4 7440-66-6 32051
13
Ofloxacin Approved Phase 4 82419-36-1 4583
14
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
15
Povidone Approved Phase 4 9003-39-8 131751496
16
Bromfenac Approved Phase 4 91714-94-2 60726
17
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
18
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
19
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
20
Travoprost Approved Phase 4 157283-68-6 5282226
21
Menthol Approved Phase 4 2216-51-5 16666
22
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
23
Calcium carbonate Approved, Investigational Phase 4 471-34-1
24
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
25
Azithromycin Approved Phase 4 83905-01-5 55185 447043
26
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
27
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
30
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
31 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
32
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
33
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
34
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
35
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
36
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
37
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
38
Betaine Approved, Nutraceutical Phase 4 107-43-7, 6915-17-9 248
39
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
40 Gallopamil Investigational Phase 4 16662-47-8
41
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
42 Carboxymethylcellulose Sodium Phase 4
43 Cathartics Phase 4
44 Castor Phase 4
45 Laxatives Phase 4
46 Neurotransmitter Agents Phase 4
47 Cholinergic Agents Phase 4
48 Muscarinic Agonists Phase 4
49 Olive Phase 4
50 Hydrocortisone 17-butyrate 21-propionate Phase 4

Interventional clinical trials:

(show top 50) (show all 879)
# Name Status NCT ID Phase Drugs
1 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
2 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
3 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
4 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
6 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
7 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
8 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
9 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
10 A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis Unknown status NCT03237936 Phase 4 1mg/mL ciclosporin
11 Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy Unknown status NCT03747614 Phase 4 Fluorometholone
12 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
13 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
14 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
15 Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study Completed NCT03608761 Phase 4 Rebamipide
16 Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva Completed NCT00438048 Phase 4 Artificial Saliva
17 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed NCT00631358 Phase 4 Maxidex
18 Quality of Life in a Portuguese Population With Primary Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
19 Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca. Completed NCT01797822 Phase 4 Dexamethasone;Artificial tear
20 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
21 The Effect of Ocular Surface Lubricant Eyedrops on Lid Parallel Conjunctival Folds (LIPCOF) and Other Signs and Symptoms of Dysfunctional Tear Syndrome Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
22 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
23 A Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye: A Randomized Controlled Trial Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
24 Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
25 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
26 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
27 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
28 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
29 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
30 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
31 Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02986750 Phase 4
32 Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry Eye Completed NCT04184999 Phase 4 dexamethasone intraocular suspension, 9%;Prednisolone Acetate 1% Oph Susp
33 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
34 A Randomized, Single-Center, Comparative Study of Rohto Dry-Aid® and Systane® Ultra in the Management of Tear Film Stability and Visual Function in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
35 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
36 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
37 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
38 The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
39 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
40 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
41 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
42 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
43 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
44 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
45 Comparison of Autologous Serum Versus Preservative Free Artificial Tear in Patients With Dry Eye Due to Systemic Isotretinoin Therapy Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
46 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
47 A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine Completed NCT00407043 Phase 4 Lotemax;Restasis
48 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
49 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
50 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4

Search NIH Clinical Center for Sjogren Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 51 :


hydroxyethyl cellulose
Linolenic Acid
Sodium Chloride
SODIUM CHLORIDE 0.9% PROCESSING SOLN
SODIUM CHLORIDE GRANULES

Cochrane evidence based reviews: sjogren's syndrome

Genetic Tests for Sjogren Syndrome

Anatomical Context for Sjogren Syndrome

MalaCards organs/tissues related to Sjogren Syndrome:

40
Eye, Salivary Gland, Pancreas, Lung, T Cells, Liver, Thyroid

Publications for Sjogren Syndrome

Articles related to Sjogren Syndrome:

(show top 50) (show all 2945)
# Title Authors PMID Year
1
Peripheral neuropathy in primary sjogren syndrome: a population-based study. 57 61
17101831 2006
2
A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome. 57 61
15485632 2004
3
Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome. 54 57
11247557 2001
4
Regulation of human leukocyte antigen expression in human conjunctival epithelium. 57 61
9888423 1999
5
Complement genes contribute sex-biased vulnerability in diverse disorders. 57
32499649 2020
6
Ocular complications of primary Sjögren syndrome in men. 57
26093285 2015
7
Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. 57
17071741 2006
8
Vogt-Koyanagi-Harada syndrome and keratoconjunctivitis sicca. 57
15059728 2004
9
In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. 57
12905478 2003
10
Assessing the severity of keratitis sicca with videokeratoscopic indices. 57
12799233 2003
11
Primary Sjögren's syndrome and deficiency of ICA69. 57
12383988 2002
12
Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. 57
11879137 2002
13
Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome. 57
11274068 2001
14
Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. 57
11013183 2000
15
Primary Sjögren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. 57
6437309 1984
16
Genetic differences between primary and secondary sicca syndrome. 57
314586 1979
17
Familial Sjögren's syndrome with associated primary salivary gland lymphoma. 57
766625 1976
18
28-Year-Old Woman With Chronic Kidney Disease, Fatigue, and Polyarthralgias. 42
33413820 2021
19
Qualitative mucin disorders in patients with primary Sjögren's syndrome: a literature review. 42
33247578 2021
20
Subacute cutaneous lupus erythematosus in a patient with Sjögren's syndrome taking terbinafine for onychomycosis. 42
33420774 2020
21
Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome. 61 54
19657778 2009
22
Autoantibody and biopsy grading are associated with expression of ICAM-1, MMP-3, and TRAIL in salivary gland mononuclear cells of Chinese patients with Sjogren's syndrome. 61 54
19332626 2009
23
ELISA subtypization of anti-ENA autoantibodies in clinical management of autoimmune diseases in Bosnia and Herzegovina. 61 54
20380108 2009
24
Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. 61 54
18617551 2008
25
Altered distribution of aquaporin 5 and its C-terminal binding protein in the lacrimal glands of a mouse model for Sjögren's syndrome. 61 54
18696337 2008
26
The role of interleukin-10 promoter polymorphisms in primary Sjogren's syndrome. 54 61
18612930 2008
27
CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. 61 54
18354239 2008
28
A fulminant case of renal vein thrombosis in a patient with autoimmune disorder and membranous nephropathy. 54 61
18480584 2008
29
Is SS-A/Ro52 a hydrogen peroxide-sensitive signaling molecule? 54 61
17184176 2007
30
Prognostic value of auto-antibodies in the serum of Omani patients with gastric cancer. 61 54
17143367 2006
31
[Prevalence of antiphospholipid antibodies in patients with primary Sjögren's syndrome]. 61 54
17195353 2006
32
Immunoglobulin VH genes in thymic MALT lymphoma are biased toward a restricted repertoire and are frequently unmutated. 61 54
16353132 2006
33
Analysis of in vivo role of alpha-fodrin autoantigen in primary Sjogren's syndrome. 61 54
16192640 2005
34
Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome. 61 54
16014536 2005
35
Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjogren's syndrome and radiation therapy. 54 61
15740707 2005
36
Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjögren's syndrome. 61 54
15692983 2005
37
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis. 54 61
15647194 2005
38
[Molecular mechanisms of salivary gland destruction in patients with Sjogren's syndrome. ]. 54 61
15744117 2005
39
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. 61 54
15694905 2005
40
Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. 61 54
15353609 2004
41
Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. 54 61
15448217 2004
42
Character of ocular surface mucins and their alteration in dry eye disease. 61 54
17216084 2004
43
[Abnormal interferon-inducible protein-10 expression in the labial glands of patients with Sjogren's syndrome]. 54 61
14650168 2003
44
Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. 54 61
12887055 2003
45
[Expression of chemokine in the labial glands of patients with Sjogren's syndrome]. 61 54
12812666 2003
46
Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. 54 61
11591123 2001
47
Possible involvement of EBV-mediated alpha-fodrin cleavage for organ-specific autoantigen in Sjogren's syndrome. 54 61
11313424 2001
48
Polymorphisms of the Ro52 gene associated with anti-Ro 52-kd autoantibodies in patients with primary Sjögren's syndrome. 61 54
11263778 2001
49
Sjögren's syndrome complicated with autoimmune hepatitis and antiphospholipid antibody syndrome. 54 61
10674855 2000
50
Amidolytic and peptidolytic activities of immunoglobulin G present in sera from patients with rheumatoid arthritis, Sjogren's syndrome and systemic lupus erythematosus. 61 54
9767453 1998

Variations for Sjogren Syndrome

Expression for Sjogren Syndrome

Search GEO for disease gene expression data for Sjogren Syndrome.

Pathways for Sjogren Syndrome

Pathways related to Sjogren Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Toll-like receptor signaling pathway hsa04620
2 JAK-STAT signaling pathway hsa04630

Pathways related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 TNFSF13B FAS CD79A CD40LG
2
Show member pathways
10.71 TNFSF13B FAS CD40LG

GO Terms for Sjogren Syndrome

Cellular components related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 LTF FAS CD40LG CALR APOH
2 extracellular space GO:0005615 9.23 TNFSF13B SIL1 LTF HSPG2 CD40LG CALR

Biological processes related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor-mediated signaling pathway GO:0033209 8.8 TNFSF13B FAS CD40LG

Sources for Sjogren Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....